Bibliography: library/10665-340190

The reference for library/10665-340190 (who-iris) and any references extracted from it. library · All references.

Export these 179 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

179 shown

  1. World Health Organization (2021). Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. World Health Organization.
    10665-340190 · catalogue · link · repository record · ISBN 9789240022232 (electronic version) · source: catalogue/records/10665-340190.dc.json · held: library/10665-340190
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. UNAIDS data. Geneva: UNAIDS; 2020 (https://www.unaids.org/en/resources/documents/2020/unaids-data, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.1.json
  3. United Nations General Assembly. Political declaration on HIV and AIDS: intensifying our efforts to eliminate HIV and AIDS. New York: United Nations; 2011 (https://www.unaids.org/en/aboutunaids/unitednationsdeclarationsandgoals/2011highlevelmeetingonaids, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.2.json
  4. On the Fast-Track to an AIDS-free generation. Geneva: UNAIDS; 2016 (https://www.unaids.org/sites/default/files/media_asset/GlobalPlan2016_en.pdf, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.3.json
  5. Consolidated guidelines on HIV prevention, diagnosis, treatment and care of key populations. Geneva: World Health Organization; 2016 (https://www.who.int/hiv/pub/guidelines/keypopulations/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.4.json
  6. Women and HIV – a spotlight on adolescent girls and young women. Geneva. UNAIDS; 2019 (https://www.unaids.org/en/resources/documents/2019/women-and-hiv, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.5.json
  7. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – second edition. Geneva: World Health Organization; 2016 (https://www.who.int/hiv/pub/arv/arv-2016/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.6.json
  8. HIV market report. Boston: Clinton Health Access Initiative; 2019 (https://www.clintonhealthaccess.org/the-state-of-the-hiv-market-in-low-and-middle-income-countries-3/, accessed 1 March 2021).
    · extracted · link · source: references/10665-340190.sec-010.7.json
  9. Making viral load routine: successes and failures in the implementation of routine HIV viral load monitoring. Geneva: Médecins Sans Frontières; 2016.
    · extracted · source: references/10665-340190.sec-010.8.json
  10. HIV molecular diagnostics toolkit to improve access to viral load testing and infant diagnosis. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/bitstream/handle/10665/325961/9789241516211-eng.pdf, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.9.json
  11. Global tuberculosis report. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789240013131, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.10.json
  12. Global health sector strategy on HIV 2016–2021. Towards ending AIDS. Geneva: World Health Organization; 2016 (https://www.who.int/hiv/strategy2016-2021/ghss-hiv/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.11.json
  13. Department of Economic and Social Affairs. Sustainable Development Goals. New York: United Nations; 2015 (https://sdgs.un.org/goals, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-010.12.json
  14. WHO handbook for guideline development. 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 4 January 2021).
    · extracted · link · source: references/10665-340190.sec-010.13.json
  15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
    · extracted · source: references/10665-340190.sec-010.14.json
  16. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973.
    · extracted · source: references/10665-340190.sec-014.1.json
  17. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (https://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.2.json
  18. UNAIDS data. Geneva: UNAIDS; 2020 (https://www.unaids.org/en/resources/documents/2020/unaids-data, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.3.json
  19. Dapivirine Vaginal Ring 25 mg (dapivirine): An overview of Dapivirine Vaginal Ring 25 mg and why it received a positive opinion. Amsterdam: European Medicines Agency 2020.
    · extracted · source: references/10665-340190.sec-014.4.json
  20. Ahmed K, Baeten JM, Beksinska M, Bekker LG, Bukusi EA, Donnell D et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394:303–13.
    · extracted · source: references/10665-340190.sec-014.5.json
  21. Celum CL, Delany-Moretlwe S, Hosek S, Dye BJ, Bekker L-G, Mgodi N. Risk behavior, perception, and reasons for PrEP among young African women in HPTN 082. Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 4–7 March 2018 (https://www.croiconference.org/abstract/risk-behavior-perception-and-reasons-prep-among-young-african-women-hptn-082, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.6.json
  22. Koss CA, Havlir DV, Ayieko J, Kwarisiima D, Kabami J, Atukunda M et al. Lower than expected HIV incidence among men and women at elevated HIV risk in a population-based PrEP study in rural Kenya and Uganda: interim results from the SEARCH study. 23rd International AIDS Conference, San Francisco, CA, USA, 6–10 July 2020 (Abstract No. 875; https://aids2020.org/wp-content/uploads/2020/07/HIV-Highlights-Press-Conference-Abstracts.pdf, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.7.json
  23. van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K et al. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21:e25094.
    · extracted · source: references/10665-340190.sec-014.8.json
  24. Montgomery ET, Beksinska M, Mgodi N, Schwartz J, Weinrib R, Browne EN et al. End‐user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. J Int AIDS Soc. 2019;22:e25283.
    · extracted · source: references/10665-340190.sec-014.9.json
  25. Marrazzo JM, Del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society–USA Panel. Jama. 2014 Jul 23;312(4):390-409.
    · extracted · source: references/10665-340190.sec-014.10.json
  26. WHO implementation tool for pre-exposure prophylaxis of HIV infection. Geneva, Switzerland: World Health Organization. 2017. (https://www.who.int/hiv/pub/prep/prep-implementation-tool/en/, accessed 21 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.11.json
  27. Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–43.
    · extracted · source: references/10665-340190.sec-014.12.json
  28. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V et al. 2016;375:2121–32.
    · extracted · source: references/10665-340190.sec-014.13.json
  29. Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. The Lancet HIV. 2021 Feb 1;8(2):e77-86.
    · extracted · source: references/10665-340190.sec-014.14.json
  30. Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. The Lancet HIV. 2021 Feb 1;8(2):e87-95.
    · extracted · source: references/10665-340190.sec-014.15.json
  31. Brown E, Hendrix C, van der Straten A, Kiweewa F, Mgodi N, Palanee‐Philips T et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV‐1 acquisition: a secondary analysis from a randomized, placebo‐controlled trial. J Int AIDS Soc. 2020;23:e25634.
    · extracted · source: references/10665-340190.sec-014.16.json
  32. Nel A, Bekker L-G, Bukusi E, Hellström E, Kotze P, Louw C et al. Safety, acceptability and countries in sub-Saharan Africa. PLoS ONE. 2016;11:e0147743.
    · extracted · source: references/10665-340190.sec-014.17.json
  33. MTN-042 – a study of PrEP and the dapivirine ring in pregnant women 2020 (https://mtnstopshiv.org/research/studies/mtn-042, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.18.json
  34. MTN-043 – B-PROTECTED: Breastfeeding PrEP & ring open-label trial 2020 (https://mtnstopshiv.org/news/studies/mtn043, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.19.json
  35. Rosenberg Z, Nel A, van Niekerk N, Van Baelen B, Van Roey J, Palanee-Phillips T et al. Pooled efficacy analysis of two Phase III trials of dapivirine vaginal ring for the reduction of HIV-1 infection risk in HIV-uninfected women in sub-Saharan Africa. 9th IAS Conference on Health Science, Paris, France, 23–26 July 2017 (http://programme.ias2017.org/Abstract/Abstract/5704, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.20.json
  36. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V et al. 2016;375:2121–32.
    · extracted · source: references/10665-340190.sec-014.21.json
  37. Nel A, Van Baelen BE, Mans W, Louw C, Gama C, Mabude Z et al. Dapivirine vaginal ring reduces the risk of HIV-1 infection among women in Africa. 9th South Africa AIDS Conference, Durban, South Africa, 11–14 June 2019.
    · extracted · source: references/10665-340190.sec-014.22.json
  38. Fonner V, Dalglish S. Dapivirine intervaginal ring as pre-exposure prophylaxis to prevent HIV among women at substantial risk of infection: a systematic review and meta-analysis. Unpublished. [Abstract available in Web Annex C.1].
    · extracted · source: references/10665-340190.sec-014.23.json
  39. Palanee-Phillips T, Roberts ST, Reddy K, Govender V, Naidoo L, Siva S et al. Impact of partner-related social harms on women's adherence to the dapivirine vaginal ring during a Phase III trial. J Acquir Immune Defic Syndr. 2018;79:580.
    · extracted · source: references/10665-340190.sec-014.24.json
  40. Balkus JE, Palanee-Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C, Kintu K et al. Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. J Acquir Immune Defic Syndr. 2017:76:e47.
    · extracted · source: references/10665-340190.sec-014.25.json
  41. Makanani B, Balkus JE, Jiao Y, Noguchi LM, Palanee-Phillips T, Mbilizi Y et al. Pregnancy J Acquir Immune Defic Syndr. 2018;79:566. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring
    · extracted · source: references/10665-340190.sec-014.26.json
  42. Kusemererwa S, Abaasa A, editors. Pregnancy incidence and outcomes among women using dapivirine vaginal ring for HIV prevention in a Phase III clinical trial in south western Uganda. AIDS Res Hum Retrovir. 2018;34:209.
    · extracted · source: references/10665-340190.sec-014.27.json
  43. Kusemererwa S, Abaasa A, editors. Does the use of the dapivirine vaginal ring result in change in risky sexual behavior? AIDS Res Hum Retrovir. 2018;34:209
    · extracted · source: references/10665-340190.sec-014.28.json
  44. Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW et al. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost– effectiveness. J Int AIDS Soc. 2019;22:e25282.
    · extracted · source: references/10665-340190.sec-014.29.json
  45. Glaubius R, Hood G, Parikh UM, Abbas U. Dapivirine vaginal ring preexposure prophylaxis for HIV prevention in South Africa. Topics Antivir Med. 2016;24:458.
    · extracted · source: references/10665-340190.sec-014.30.json
  46. Smith J, Garnett G, Van Damme L, Hallett T. Cost–effectiveness of the intravaginal dapivirine ring: a modeling analysis. 23rd Conference on Retroviruses and Opportunistic Infections, 22–25 February 2016 (https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01250294/full, accessed 4 February 2021).
    · extracted · doi:10.1002/central/CN-01250294/full · source: references/10665-340190.sec-014.31.json
  47. Reidy M, Gardiner E, Pretorius C, Glaubius R, Torjesen K, Kripke K. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. PLoS One. 2019;14:e0218710.
    · extracted · source: references/10665-340190.sec-014.32.json
  48. Kripke K, Reidy M, Bhavaraju N, Torjesen K, Gardiner E. Modeling the potential impact of the dapivirine ring for HIV prevention. 22nd International AIDS Society Conference, Amsterdam, Netherlands, 23–27 July 2018 (https://www.prepwatch.org/wp-content/uploads/2018/08/OPTIONS_DapRingModeling_AIDS2018poster-1.pdf, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.33.json
  49. Nel A, Haazen W, Nuttall J, Romano J, Rosenberg Z, van Niekerk N. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28:1479–87.
    · extracted · source: references/10665-340190.sec-014.34.json
  50. Chen BA, Zhang J, Gundacker HM, Hendrix CW, Hoesley CJ, Salata RA et al. Phase 2a safety, pharmacokinetics, and acceptability of dapivirine vaginal rings in US postmenopausal women. Clin Infect Dis. 2019;68:1144–51.
    · extracted · source: references/10665-340190.sec-014.35.json
  51. Bunge KE, Levy L, Szydlo DW, Zhang J, Gaur AH, Reirden D et al. Brief report: Phase IIa safety study of a vaginal ring containing dapivirine in adolescent young women. J Acquir Immune Defic Syndr. 2020;83:135–9.
    · extracted · source: references/10665-340190.sec-014.36.json
  52. Griffin JB, Ridgeway K, Montgomery E, Torjesen K, Clark R, Peterson J et al. Vaginal ring acceptability and related preferences among women in low-and middle-income countries: a systematic review and narrative synthesis. PLoS One. 2019;14:e0224898.
    · extracted · source: references/10665-340190.sec-014.37.json
  53. Schwartz K, Bhavaraju N, Ridgeway K, Gomez A. End-user perspectives on their ability, motivation and opportunity to use the dapivirine vaginal ring. 23rd International AIDS Conference, San Francisco, CA, USA, 6–10 July 2020.
    · extracted · source: references/10665-340190.sec-014.38.json
  54. Ridgeway KM, Smith K, Torjesen K, van der Straten A, Achilles SL. Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world. Submitted.
    · extracted · source: references/10665-340190.sec-014.39.json
  55. Nel A, Bekker LG, Bukusi E, Hellström E, Kotze P, Louw C et al. Safety, acceptability and countries in sub-Saharan Africa. PLoS One. 2016;11:e0147743.
    · extracted · source: references/10665-340190.sec-014.40.json
  56. van der Straten A, Laborde N, Hoesley CJ, Cheng H, Husnik MJ. Adherence and acceptability of a multidrug vaginal ring for HIV prevention in a Phase I study in the United States. AIDS Behav. 2016;20:2644–2653.
    · extracted · source: references/10665-340190.sec-014.41.json
  57. Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31:1159.
    · extracted · source: references/10665-340190.sec-014.42.json
  58. Chitukuta M, Duby Z, Katz A, Nakyanzi T, Reddy K, Palanee-Phillips T et al. Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa. Culture Health Sexuality. 2019;21:1209–24.
    · extracted · source: references/10665-340190.sec-014.43.json
  59. Duby Z, Katz AW, Browne EN, Mutero P, Etima J, Zimba CC et al. Hygiene, blood flow, and vaginal overload: why women removed an HIV prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2020;24:617–28.
    · extracted · source: references/10665-340190.sec-014.44.json
  60. Laborde ND, Pleasants E, Reddy K, Atujuna M, Nakyanzi T, Chitukuta M et al. Impact of the dapivirine vaginal ring on sexual experiences and intimate partnerships of women in an HIV prevention clinical trial: managing ring detection and hot sex. AIDS Behav. 2018;22:437–46.
    · extracted · source: references/10665-340190.sec-014.45.json
  61. Nair G, Roberts S, Baeten J, Palanee-Philips T, Katie S, Reddy K et al. Disclosure of vaginal ring use to male partners in an HIV prevention study: impact on adherence. AIDS Res Hum Retrovir. 2018;34:209.
    · extracted · source: references/10665-340190.sec-014.46.json
  62. van der Straten A, Browne EN, Shapley-Quinn MK, Brown ER, Reddy K et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81:304–10.
    · extracted · source: references/10665-340190.sec-014.47.json
  63. Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009. Global Health: Science and Practice. 2013 Aug 1;1(2):203-12.
    · extracted · source: references/10665-340190.sec-014.48.json
  64. Consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2019 (https://www.who.int/hiv/pub/guidelines/hiv-testing-services/en/, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.49.json
  65. Makanani B, Balkus JE, Jiao Y, Noguchi LM, Palanee-Phillips T, Mbilizi Y et al. Pregnancy J Acquir Immune Defic Syndr. 2018;79:566.
    · extracted · source: references/10665-340190.sec-014.50.json
  66. NCT03074786: MTN-034/REACH (Reversing the Epidemic in Africa with Choices in HIV Prevention) 2020 (https://clinicaltrials.gov/ct2/show/NCT03074786, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-014.51.json
  67. AIDSInfo [online database]. Geneva: UNAIDS; 2020 (http://aidsinfo.unaids.org, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.1.json
  68. Bourne DE, Thompson M, Brody LL, Cotton M, Draper B, Laubscher R et al. Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa. AIDS. 2009;23:101–6.
    · extracted · source: references/10665-340190.sec-021.2.json
  69. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–44.
    · extracted · source: references/10665-340190.sec-021.3.json
  70. Markby J, Boeke C, Sacks J, Wang M, Peter T, Vojnov L. HIV early infant diagnosis testing programs in low- and middle-income countries: a systematic review and meta-analysis. In preparation.
    · extracted · source: references/10665-340190.sec-021.4.json
  71. WHO list of prequalified in vitro diagnostic products. Geneva: World Health Organization; 2020 (https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/public_report/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.5.json
  72. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – second edition. Geneva: World Health Organization; 2016 (https://www.who.int/hiv/pub/arv/arv-2016/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.6.json
  73. Luo R, Boeras D, Vojnov L. Systematic review on the clinical impact of point-of-care early infant diagnosis for HIV. In preparation. [Abstract available in Web Annex C.1].
    · extracted · source: references/10665-340190.sec-021.7.json
  74. Bianchi F, Cohn J, Sacks E, Bailey R, Lemaire JF, Machekano R et al. Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: an observational study in eight African countries. Lancet HIV. 2019;6:e373–81.
    · extracted · source: references/10665-340190.sec-021.8.json
  75. Boeke C, Wang M, Abate Z. Point-of-care testing can achieve same-day diagnosis for infants and rapid ART initiation: results from government programs across six African countries. Unpublished.
    · extracted · source: references/10665-340190.sec-021.9.json
  76. Jani IV, Meggi B, Loquiha O, Tobaiwa O, Mudenyanga C, Zitha A et al. Effect of point-of-care early infant diagnosis on antiretroviral therapy initiation and retention of patients. AIDS. 2018;32:1453–63.
    · extracted · source: references/10665-340190.sec-021.10.json
  77. Chibwesha CJ, Mollan KR, Ford CE, Shibemba A, Saha PT, Lusaka M et al. A randomised trial of point-of-care early infant HIV diagnosis. (https://ssrn.com/abstract=3646123, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.11.json
  78. Mwenda R, Fong Y, Magombo T, Saka E, Midiani D, Mwase C, Kandulu J et al. Significant patient impact observed upon implementation of point-of-care early infant diagnosis technologies in an observational study in Malawi. Clin Infect Dis. 2018;67:701–7.
    · extracted · source: references/10665-340190.sec-021.12.json
  79. Spooner E, Govender K, Reddy T, Ramjee G, Mbadi N, Singh S et al. Point-of-care HIV testing best practice for early infant diagnosis: an implementation study. BMC Public Health. 2019;19:1–14.
    · extracted · source: references/10665-340190.sec-021.13.json
  80. Technau K-G, Kuhn L, Coovadia A, Murnane PM, Sherman G. Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation study. Lancet HIV. 2017;4:e442–8.
    · extracted · source: references/10665-340190.sec-021.14.json
  81. Le Roux S, Myer L, Vojnov L. Cost–effectiveness of point-of-care nucleic acid testing for early infant diagnosis of HIV compared to centralized, laboratory-based testing: a systematic review of mathematical modelling studies. In preparation. [Abstract available in Web Annex C.1].
    · extracted · source: references/10665-340190.sec-021.15.json
  82. Salvatore PP, de Broucker G, Vojnov L, Moss WJ, Dowdy DW, Sutcliffe CG. Modeling the cost-effectiveness of point-of-care platforms for infant diagnosis of HIV in sub-Saharan African countries. AIDS. 2021 Feb 2;35(2):287-97.
    · extracted · source: references/10665-340190.sec-021.16.json
  83. De Broucker G, Salvatore PP, Mutembo S, et al. The cost-effectiveness of scaling-up rapid point-of-care testing for early infant diagnosis of HIV in southern Zambia. Unpublished.
    · extracted · source: references/10665-340190.sec-021.17.json
  84. Frank SC, Cohn J, Dunning L, Sacks E, Walensky RP, Mukherjee S et al. Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. Lancet HIV. 2019;6:e182–90.
    · extracted · source: references/10665-340190.sec-021.18.json
  85. McCann NC, Cohn J, Flanagan C, Sacks E, Mukherjee S, Walensky RP et al. Strengthening existing laboratory-based systems vs. investing in point-of-care assays for early infant diagnosis of HIV: a model-based cost–effectiveness analysis. J Acquir Immune Defic Syndr. 2020;84(Suppl. 1):S12–21.
    · extracted · source: references/10665-340190.sec-021.19.json
  86. Katirayi L, Ochuka B, Mafaune H, Chadambuka A, Baffour T, Sacks E. “We need it the same day”: a qualitative study of caregivers and community members’ perspectives toward the use of point-of-care early infant diagnosis. J Acquir Immune Defic Syndr. 2020;84:S49–55.
    · extracted · source: references/10665-340190.sec-021.20.json
  87. Bianchi F, Clemens S, Arif Z, Sacks E, Cohn J. Acceptability of routine point-of-care early infant diagnosis in eight African countries: findings from a qualitative assessment of clinical and laboratory personnel. J Acquir Immune Defic Syndr. 2020;84:S41–8.
    · extracted · source: references/10665-340190.sec-021.21.json
  88. Ochodo EA, Guleid F, Mallett S, Deeks JJ. Point-of-care tests detecting HIV nucleic acids for diagnosis of HIV infection in infants and children aged 18 months or less. Cochrane Database Syst Rev. 2018;(1):CD013207.
    · extracted · source: references/10665-340190.sec-021.22.json
  89. Silva DS. Ethical and equity considerations regarding the potential future implementation of HIV/AIDS novel diagnostics. [See Web Annex C.2].
    · extracted · source: references/10665-340190.sec-021.23.json
  90. HIV diagnosis and ARV use in HIV-exposed infants: a programmatic update. Geneva: World Health Organization; 2018 (https://www.who.int/hiv/pub/paediatric/diagnosis-arv-infants/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.24.json
  91. HIV market report. Boston: Clinton Health Access Initiative; 2020 (Issue 11). (https://www.clintonhealthaccess.org/the-state-of-the-hiv-market-in-low-and-middle-income-countries-3/, Accessed 1 March 2021).
    · extracted · link · source: references/10665-340190.sec-021.25.json
  92. WHO list of prequalified in vitro diagnostic products. Geneva: World Health Organization; 2020 (https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/public_report/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.26.json
  93. Le Roux S, Myer L, Vojnov L. Clinical and operational impact of point-of-care compared to laboratory-based nucleic acid testing for routine HIV viral load monitoring: a systematic review and meta-analysis. In preparation. [Abstract available in Web Annex C.1].
    · extracted · source: references/10665-340190.sec-021.27.json
  94. Drain PK, Dorward J, Violette LR, Quame-Amaglo J, Thomas KK, Samsunder N et al. Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (stream): findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV. 2020;7:e229–37.
    · extracted · source: references/10665-340190.sec-021.28.json
  95. Boeke CE, Joseph J, Atem C, Banda C, Coulibaly KD, Doi N, Gunda A, Kandulu J, Kiernan B, Kingwara L, Maokola W. Evaluation of near point‐of‐care viral load implementation in public health facilities across seven countries in sub‐Saharan Africa. Journal of the International AIDS Society. 2021 Jan;24(1):e25663.
    · extracted · source: references/10665-340190.sec-021.29.json
  96. Ndlovu Z, Fajardo E, Mbofana E, Maparo T, Garone D, Metcalf C et al. Multidisease testing for HIV and TB using the GeneXpert platform: a feasibility study in rural Zimbabwe. PLoS One. 2018;13:e0193577.
    · extracted · source: references/10665-340190.sec-021.30.json
  97. Mangone E, Cintron C, Haider R, Johns B, Avila C, Vartanova Y. Cost–effectiveness analysis of nationally scaled point-of-care diagnostic platforms compared to central laboratory models for routine viral load monitoring of HIV-positive Kenyans on antiretroviral therapy. 22nd International AIDS Society Conference, Amsterdam, Netherlands, 23–27 July 2018.
    · extracted · source: references/10665-340190.sec-021.31.json
  98. de Necker M, de Beer JC, Stander MP, Connell CD, Mwai D. Economic and public health impact of decentralized HIV viral load testing: a modelling study in Kenya. PLoS One. 2019;14:e0212972.
    · extracted · source: references/10665-340190.sec-021.32.json
  99. Girdwood S Crompton T, Sharma M, Dorward J, Garrett N, Drain PK et al. Cost– effectiveness of adoption strategies for point-of-care HIV viral load monitoring in South Africa. EClinicalMedicine. 2020;28:100607.
    · extracted · source: references/10665-340190.sec-021.33.json
  100. Bwana P, Ageng’o J, Danda J, Mbugua J, Handa A, Mwau M. Performance and usability of mPIMA™ HIV 1/2 viral load test in point of care settings in Kenya. J Clin Virol. 2019;121:104202.
    · extracted · source: references/10665-340190.sec-021.34.json
  101. Bwana P, Ageng’o J, Mwau M. Performance and usability of Cepheid GeneXpert HIV-1 qualitative and quantitative assay in Kenya. PLoS One. 2019;14:e0213865.
    · extracted · source: references/10665-340190.sec-021.35.json
  102. Habiyambere V, Ford N, Low-Beer D, Nkengasong J, Sands A, Pérez González M et al. Availability and use of HIV monitoring and early infant diagnosis technologies in WHO Member States in 2011–2013: analysis of annual surveys at the facility level. PLoS Med. 2016;13:e1002088.
    · extracted · source: references/10665-340190.sec-021.36.json
  103. Kufa T, Mazanderani AH, Sherman GG, Mukendi A, Murray T, Moyo F et al. Point‐of‐care HIV maternal viral load and early infant diagnosis testing around time of delivery at tertiary obstetric units in South Africa: a prospective study of coverage, results return and turn‐ around times. J Int AIDS Soc. 2020;23:e25487.
    · extracted · source: references/10665-340190.sec-021.37.json
  104. Mashamba-Thompson T, Sartorius B, Drain P. Operational assessment of point-of-care diagnostics in rural primary healthcare clinics of KwaZulu-Natal, South Africa: a cross-sectional survey. BMC Health Serv Res. 2018;18:380.
    · extracted · source: references/10665-340190.sec-021.38.json
  105. Nicholas S, Poulet E, Wolters L, Wapling J, Rakesh A, Amoros I et al. Point‐of‐care viral load monitoring: outcomes from a decentralized HIV programme in Malawi. J Int AIDS Soc. 2019;22:e25387.
    · extracted · source: references/10665-340190.sec-021.39.json
  106. Villa G, Abdullahi A, Owusu D, Smith C, Azumah M, Sayeed L et al. Determining virological sub-Saharan Africa. EClinicalMedicine. 2020;18:100231.
    · extracted · source: references/10665-340190.sec-021.40.json
  107. Making viral load routine: successes and failures in the implementation of routine HIV viral load monitoring Geneva: Médecins Sans Frontières; 2016.
    · extracted · source: references/10665-340190.sec-021.41.json
  108. Sacks JA, Fong Y, Gonzalez MP, Andreotti M, Baliga S, Garrett N et al. Performance of Cepheid Xpert HIV-1 viral load plasma assay to accurately detect treatment failure. AIDS. 2019;33:1881–9.
    · extracted · source: references/10665-340190.sec-021.42.json
  109. Mariani D, de Azevedo M, Vasconcellos I, Ribeiro L, Alves C, Ferreira Jr OC et al. The performance of a new point-of-care HIV virus load technology to identify patients failing antiretroviral treatment. J Clin Virol. 2020;122:104212.
    · extracted · source: references/10665-340190.sec-021.43.json
  110. Cepheid’s HBDC (High Burden Developing Country program). Sunnyvale (CA) Cepheid Subsidary, Danaher Corporation; 2011 (https://www.cepheidlegacy.com/uk/cepheid-solutions/hbdc-program#:~:text=Cepheid%20is%20an%20active%20participant,Melinda%20Gates%20Foundation%20and%20others, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.44.json
  111. Update of recommendations on first- and second-line antiretroviral regimens. Geneva: World Health Organization; 2019 (https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/, accessed 4 February 2021).).
    · extracted · link · source: references/10665-340190.sec-021.45.json
  112. HIV drug resistance report 2019. Geneva: World Health Organization; 2019 (https://www.who.int/hiv/pub/drugresistance/hivdr-report-2019/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.46.json
  113. Broyles LN, Boeras D, Luo R, Vojnov L. The viral load monitoring algorithm in people living with HIV on antiretroviral therapy: review of the literature to inform the WHO HIV guidelines. Unpublished. [Abstract available in Web Annex C.1].
    · extracted · source: references/10665-340190.sec-021.47.json
  114. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393:143–55.
    · extracted · source: references/10665-340190.sec-021.48.json
  115. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381:803–15.
    · extracted · source: references/10665-340190.sec-021.49.json
  116. The NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of HIV-1. N Engl J Med. 2019;381:816–26.
    · extracted · source: references/10665-340190.sec-021.50.json
  117. Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073–82.
    · extracted · source: references/10665-340190.sec-021.51.json
  118. Rossetti B, Baldin G, Sterrantino G, Rusconi S, De Vito A, Giacometti A et al. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicentre cohort study. Antiviral Res. 2019;169:104552.
    · extracted · source: references/10665-340190.sec-021.52.json
  119. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48-week results from the randomised open-label Phase 3b study. Lancet. 2014;383:2222–31.
    · extracted · source: references/10665-340190.sec-021.53.json
  120. ARROW Trial Team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381:1391–403.
    · extracted · source: references/10665-340190.sec-021.54.json
  121. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P et al. Nevirapine versus rtonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012;366:2380–9.
    · extracted · source: references/10665-340190.sec-021.55.json
  122. Gregson J, Tang M, Ndembi N, Hamers RL, Rhee SY, Marconi VC et al. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16:565–75.
    · extracted · source: references/10665-340190.sec-021.56.json
  123. Hamers RL, Sigaloff KCE, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54:1660–9.
    · extracted · source: references/10665-340190.sec-021.57.json
  124. Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis. J Int AIDS Soc. 2019;22:e25415.
    · extracted · source: references/10665-340190.sec-021.58.json
  125. Villa G, Abdullahi A, Owusu D, Smith C, Azumah M, Sayeed L et al. Determining virological sub-Saharan Africa. EClinicalMedicine. 2020;18:100231.
    · extracted · source: references/10665-340190.sec-021.59.json
  126. Birungi J, Cui Z, Okoboi S, Kapaata A, Munderi P, Mukajjanga C et al. Lack of effectiveness of adherence counselling in reversing virological failure among patients on long‐term antiretroviral therapy in rural Uganda. HIV Med. 2020;21:21–9.
    · extracted · source: references/10665-340190.sec-021.60.json
  127. Hermans LE, Carmona S, Nijhuis M, Tempelman HA, Richman DD, Moorhouse M et al. Virological suppression and clinical management in response to viremia in South African HIV treatment program: a multicenter cohort study. PLoS Med. 2020;17:e1003037.
    · extracted · source: references/10665-340190.sec-021.61.json
  128. De Luca A, Sidumo ZJ, Zanelli G, Magid NA, Luhanga R, Brambilla D et al. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. BMC Infect Dis. 2017;17:1–6.
    · extracted · source: references/10665-340190.sec-021.62.json
  129. Values and preferences survey to inform the development of the Guideline on HIV prevention, infant diagnosis, antiretroviral therapy initiation and monitoring. Geneva: World Health Organization. [See Web Annex C.3].
    · extracted · source: references/10665-340190.sec-021.63.json
  130. Phillips A, Bansi-Matharu L, Cambiano V, HIV Modelling Consortium. Modelled evaluation of modifications in viral load monitoring in the context of sub-Saharan Africa: modelling to inform WHO guidance. (https://doi.org/10.6084/m9.figshare.13259219.v1, accessed 9 February 2021).
    · extracted · doi:10.6084/m9.figshare.13259219.v1 · source: references/10665-340190.sec-021.64.json
  131. Shroufi A, Van Cutsem G, Cambiano V, Bansi-Matharu L, Duncan K, Murphy RA et al. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure. AIDS. 2019;33:1635–44.
    · extracted · source: references/10665-340190.sec-021.65.json
  132. HIV molecular diagnostics toolkit to improve access to viral load testing and infant diagnosis. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/bitstream/handle/10665/325961/9789241516211-eng.pdf, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-021.66.json
  133. Luo R, Boeras D, Broyles L, Vojnov L. Systematic review of the HIV viral load threshold for treatment failure: impacts on disease progression, drug resistance, and HIV transmission. In preparation. [Abstract available in Web Annex C.1].
    · extracted · source: references/10665-340190.sec-021.67.json
  134. Mofenson L. Mother-to-child transmission review. Unpublished. 2020.
    · extracted · source: references/10665-340190.sec-021.68.json
  135. Vojnov L, Fong Y, Prescott M, Ford N, Carmona S, Zeh C et al. A meta-analysis of using dried blood spots for viral load testing with lower treatment failure thresholds. Submitted.
    · extracted · source: references/10665-340190.sec-021.69.json
  136. Vojnov L, Carmona S, Zeh C, Markby J, Boeras D, Prescott MR et al. Dried blood spot samples for viral load testing can be used with most currently available viral load technologies: a pooled data meta-analysis. Submitted.
    · extracted · source: references/10665-340190.sec-021.70.json
  137. Global tuberculosis report. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789240013131, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-025.1.json
  138. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – second edition. Geneva: World Health Organization; 2016 (https://www.who.int/hiv/pub/arv/arv-2016/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-025.2.json
  139. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-025.3.json
  140. Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N et al. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis. 2012;12:1–9.
    · extracted · source: references/10665-340190.sec-025.4.json
  141. Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis. 2014;14:563–71.
    · extracted · source: references/10665-340190.sec-025.5.json
  142. Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A et al. Efficacy and safety of antiretroviral therapy initiated one week after tuberculosis therapy in patients with CD4 counts <200 cells/μL: TB-HAART Study, a randomized clinical trial. PLoS One. 2015;10:e0122587.
    · extracted · source: references/10665-340190.sec-025.6.json
  143. Merle CS, Floyd S, Ndiaye A, Galperine T, Furco A, De Jong BC et al. High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of TB/HIV co-infected patients: the RAFA trial results. J Int AIDS Soc. 2016;19:38–9.
    · extracted · source: references/10665-340190.sec-025.7.json
  144. Shao HJ, Crump JA, Ramadhani HO, Uiso LO, Ole-Nguyaine S, Moon AM et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses. 2009;25:1277–85.
    · extracted · source: references/10665-340190.sec-025.8.json
  145. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697– 706.
    · extracted · source: references/10665-340190.sec-025.9.json
  146. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–501.
    · extracted · source: references/10665-340190.sec-025.10.json
  147. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–91.
    · extracted · source: references/10665-340190.sec-025.11.json
  148. Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471–81.
    · extracted · source: references/10665-340190.sec-025.12.json
  149. Merle C. RAFA trial sub-analysis. In preparation.
    · extracted · source: references/10665-340190.sec-025.13.json
  150. Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M et al. Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020;70·549–56.
    · extracted · source: references/10665-340190.sec-025.14.json
  151. Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine. 2020:100573. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring
    · extracted · source: references/10665-340190.sec-025.15.json
  152. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377:233–45.
    · extracted · source: references/10665-340190.sec-025.16.json
  153. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-025.17.json
  154. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). Geneva: World Health Organization; 2017 (https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-025.18.json
  155. Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013;382:1555–63.
    · extracted · source: references/10665-340190.sec-025.19.json
  156. Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, Musoke P, Siberry G et al. Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation. J Int AIDS Soc. 2017;20:21552.
    · extracted · source: references/10665-340190.sec-025.20.json
  157. Van Rie A, Sawry S, Link-Gelles R, Madhi S, Fairlie L, Verwey C et al. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. Pediatr Pulmonol. 2016;51:157–64.
    · extracted · source: references/10665-340190.sec-025.21.json
  158. Cotton MF, Rabie H, Nemes E, Mujuru H, Bobat R, Njau B et al. A prospective study of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected children from high prevalence countries. PLoS One. 2019;14:e0211155.
    · extracted · source: references/10665-340190.sec-025.22.json
  159. Hannock Tweya AJ, Heller T. Initiating TB treatment and ART at the same time – observations and experiences from Martin-Preuss Center, Lilongwe, Malawi. [Personal communication].
    · extracted · source: references/10665-340190.sec-025.23.json
  160. Kerschberger B, Jobanputra K, Schomaker M, Kabore SM, Teck R, Mabhena E et al. Feasibility of antiretroviral therapy initiation under the treat‐all policy under routine conditions: a prospective cohort study from Eswatini. J Int AIDS Soc. 2019;22:e25401.
    · extracted · source: references/10665-340190.sec-025.24.json
  161. Guideline on HIV disclosure counselling for children up to 12 years of age. Geneva: World Health Organization; 2011 (https://www.who.int/hiv/pub/hiv_disclosure/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-025.25.json
  162. HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV: recommendations for a public health approach and considerations for policy-makers and managers. Geneva: World Health Organization; 2013 (https://www.who.int/hiv/pub/guidelines/adolescents/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-025.26.json
  163. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J et al. Prednisone for the prevention of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2018;379:1915–25.
    · extracted · source: references/10665-340190.sec-025.27.json
  164. Stek C, Allwood B, Du Bruyn E, Buyze J, Schutz C, Thienemann F et al. The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function. Eur Respir J. 2020;55:1901692.
    · extracted · source: references/10665-340190.sec-025.28.json
  165. Burke R, Macpherson P, Rickman H, Singh S, Hosseinipour M, Wilkinson RJ et al. What tuberculosis symptoms preclude safe same-day ART initiation? [Abstract available in Web Annex C.1]
    · extracted · source: references/10665-340190.sec-028.1.json
  166. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-028.2.json
  167. Global tuberculosis report. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789240013131, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-028.3.json
  168. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-028.4.json
  169. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8:e1000391.
    · extracted · source: references/10665-340190.sec-028.5.json
  170. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://www.who.int/tb/publications/ICF_IPTguidelines/en, accessed 4 February 2021).
    · extracted · link · source: references/10665-340190.sec-028.6.json
  171. Rosen S, Maskew M, Larson BA, Brennan AT, Tsikhutsu I, Fox MP et al. Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): results from an individually randomized trial in South Africa and Kenya. PLoS Med. 2019;16:e1002912.
    · extracted · source: references/10665-340190.sec-028.7.json
  172. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. The Lancet HIV. 2018;5:e515-e23. accessed 4 February 2021.
    · extracted · source: references/10665-340190.sec-028.8.json
  173. Update of the WHO guidance on screening for active tuberculosis. Geneva World Health Organization; 15 June 2020 (https://www.who.int/news/item/15-06-2020-update-of-the-who-guidance-on-screening-for-active-tuberculosis).
    · extracted · link · source: references/10665-340190.sec-028.9.json
  174. Maskew M, Brennan AT, Fox MP, Vezi L, Venter WD, Ehrenkranz P et al. A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: the SLATE II individually randomized clinical trial. PLoS Med. 2020;17:e1003226.
    · extracted · source: references/10665-340190.sec-028.10.json
  175. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G et al. Correction: initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13:e1002050.
    · extracted · source: references/10665-340190.sec-028.11.json
  176. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS medicine. 2016;13:e1002015.
    · extracted · source: references/10665-340190.sec-028.12.json
  177. Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A,et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE Randomized Clinical Trial. JAMA. 2018;319:1103–12.
    · extracted · source: references/10665-340190.sec-028.13.json
  178. Scott NA, Maskew M, Fong RM, Olson IE, Brennan AT, Fox MP et al. Patients’ perceptions of quality on the process of same-day initiation of antiretroviral therapy and their early treatment experience. Patient. https://doi.org/10.1007/s40271-020-00437-4.
    · extracted · doi:10.1007/s40271-020-00437-4 · source: references/10665-340190.sec-028.14.json
  179. Hannock Tweya AJ, Heller T. Initiating TB treatment and ART at the same time – observations and experiences from Martin-Preuss Center, Lilongwe, Malawi. Unpublished.
    · extracted · source: references/10665-340190.sec-028.15.json